Trump Administration Enacts Divergent Drug Policies: Permissive Rescheduling of Cannabis and Psychedelics Coincides with Militarized Enforcement and Reductions in Harm Reduction Funding
Introduction
On April 18, 2025, President Donald Trump signed an executive order to expedite the approval process for psychedelic drugs, following a December 2024 directive to reschedule cannabis to Schedule III. These actions represent the most significant federal liberalization of controlled substances since the initiation of the war on drugs in 1971. Concurrently, the administration has intensified enforcement against fentanyl, designated it as a weapon of mass destruction, and reduced funding for harm reduction programs and addiction treatment infrastructure.
Main Body
The December 2024 executive order instructed the Drug Enforcement Administration (DEA) to complete rulemaking for moving medical marijuana from Schedule I to Schedule III, a change that was subsequently enacted. The April 2025 order for psychedelics, specifically serotonin 2a agonists such as psilocybin and LSD derivatives, included the issuance of three Commissioner's National Priority Vouchers by the Food and Drug Administration (FDA), which collapse the standard review timeline from months to weeks. Companies studying psilocybin for treatment-resistant depression and methylone for post-traumatic stress disorder received these vouchers. The stock price of Compass Pathways, a synthetic psilocybin manufacturer, increased by 42 percent following the announcement. These moves contrast with prior administrations: Jimmy Carter's decriminalization attempt in 1977 was blocked by Congress; Barack Obama's memos deprioritized federal enforcement but did not reschedule cannabis; and Joe Biden's rescheduling initiative stalled in administrative litigation before leaving office. The rescheduling of medical marijuana applies exclusively to FDA-approved products and state-licensed medical marijuana businesses, excluding recreational cannabis. This change has significant implications for research, particularly in Colorado, where medical marijuana has been legal since 2001. Shannon Donnelly, a professor at Metropolitan State University of Denver, noted that the federal government had previously limited researchers to a single federally licensed source for cannabis. Under the new rules, state-licensed medical marijuana cultivators in Colorado may supply research-grade cannabis directly to scientists. This expanded access allows investigation into specific cannabinoids and terpenes for conditions such as anxiety, insomnia, and cancer. The Institute of Cannabis Research, a state-funded organization, can now pursue a broader scope of studies. Donnelly stated that the rescheduling effectively signals federal acknowledgment of medical claims made by consumers. Simultaneously, the administration has pursued a contrasting set of policies. In July 2025, an executive order barred federal grants for harm reduction programs, including syringe services and naloxone distribution. The Substance Abuse and Mental Health Services Administration (SAMHSA) lost approximately half its staff, and the National Survey on Drug Use and Health team was eliminated. The Department of Health and Human Services terminated roughly $2 billion in SAMHSA grants before reversing course after bipartisan opposition. Illicit fentanyl was designated as a Weapon of Mass Destruction, triggering military and intelligence involvement in enforcement. The HALT Fentanyl Act imposed 10-year mandatory minimum sentences for possession of 100 grams or more. Military strikes were authorized on suspected drug vessels in the Caribbean and Eastern Pacific. Overdose deaths had been declining—87,000 in the 12 months ending September 2024—a trend predating these cuts and reflecting prior public health investments. Differing perspectives on this policy contradiction were expressed. Jeffrey Singer, a physician and drug-policy analyst, stated that while the rescheduling and psychedelics orders represent genuine progress, the administration is simultaneously intensifying the war on drugs, including targeting traffickers at sea. He noted that from a libertarian viewpoint, government should not fund harm reduction but should not obstruct private provision either. Maritza Perez Medina of the Drug Policy Alliance characterized the contradiction as deliberate, arguing that the administration uses fentanyl as a pretext for military escalation while cutting access to lifesaving care. Kevin Sabet of Smart Approaches to Marijuana criticized the permissiveness, stating that the policy is being dictated by podcasters and active addicts. Dimitri Mugianis and Ross Ellenhorn of Cardea warned that the administration's tax and spending legislation would cut over $1 trillion from Medicaid and food assistance, undermining recovery capital. The selective nature of the policy is historically notable. No president since Richard Nixon has moved so far on making controlled substances accessible, yet the administration has simultaneously adopted the most militarized enforcement posture in modern history. Singer noted that previous federal retreats, such as Carter's decriminalization attempt and Obama's Ogden memo, were limited compared to formal rescheduling. The political calculus appears to reflect public opinion: support for marijuana legalization has risen from 23 percent in 1985 to 64 percent currently, according to Gallup. Psychedelics are associated with treating PTSD and are viewed favorably. Singer pointed out that many drugs classified as 'hard' are already used medically, and that prohibition often leads to more dangerous black-market products. Jeffrey Miron, a Harvard economist, argued that legalization would not dramatically increase use but would make use safer through regulation. The future trajectory remains uncertain. If the DEA finalizes the Schedule III rule and the FDA approves at least one psychedelic by late 2027, the administration will have opened a door that predecessors only discussed. However, the window appears limited to politically palatable substances. Miron emphasized that execution matters more than rhetoric, and that Trump's orders were directives rather than requests for review. The real test is whether cannabis and psychedelics become a proof of concept for broader reform, or remain a narrow carve-out.
Conclusion
The current drug policy under the Trump administration is characterized by a paradoxical combination of permissiveness for cannabis and psychedelics and militarized enforcement for fentanyl, alongside reductions in harm reduction and addiction treatment funding. While the rescheduling of medical marijuana has opened new research pathways in states like Colorado, the simultaneous dismantling of public health infrastructure and escalation of enforcement actions create a contradictory landscape. The long-term implications depend on subsequent regulatory decisions and whether the administration's selective approach leads to broader reform or remains confined to substances with public support.